U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H14ClN.ClH
Molecular Weight 220.139
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CHLORPHENTERMINE HYDROCHLORIDE

SMILES

Cl.CC(C)(N)CC1=CC=C(Cl)C=C1

InChI

InChIKey=WEJDYJKJPUPMLH-UHFFFAOYSA-N
InChI=1S/C10H14ClN.ClH/c1-10(2,12)7-8-3-5-9(11)6-4-8;/h3-6H,7,12H2,1-2H3;1H

HIDE SMILES / InChI
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C10H14ClN
Molecular Weight 183.678
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/13931448 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2274216/pdf/canfamphys00340-0041.pdf

Chlorphentermine exerts anorectic properties. It is a synthetic amphetamine derivatc claimed to have none of the excitatory effects of the parenit substanice. PRE-SATE (Chlorphentermine HCl) is an effective appetite suppressant with a pattern of pharmacologic action substantially different from those of traditional anorexigenics. In providing dependable appetite control with appreciable loss of bodyweight, PRE-SATE does not significantly increase central nervous system (CNS), cardiorespiratory or metabolic activity.

CNS Activity

Approval Year

1965
159
Targets

Targets

Primary TargetPharmacologyConditionPotency
Substrate
661
 338.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
PRE-SATE

Approved Use

PRE-SATE is indicated as an adlunct in the short term (i.e. a few weeks) management of exogenous obesity and related less serious overweight conditions in conjunction with a medically supervised regimen of weight reduction based on caloric restriction.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.4 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/5416167/
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPHENTERMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
10.6 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/5416167/
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPHENTERMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
41 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/5416167/
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORPHENTERMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
Sourcing

Sourcing

Vendor/AggregatorIDURL
3A SpeedChemical Inc
SG-09490
http://www.speedchemical.com/products2_id_3483.html
abcr GmbH
AB536530
http://www.abcr.com/shop/en/AB536530
Achemtek
0102-019917
http://www.achemtek.com/461-78-9
Ambinter
Amb1058845
http://www.ambinter.com/reference/1058845
Aurora Fine Chemicals LLC
A00.359.866
http://online.aurorafinechemicals.com/info?ID=A00.359.866
ChemMol
99086785
http://www.chemmol.com/chemmol/99086785.html
ChemShuttle
180324
http://www.chemshuttle.com/catalogsearch/result/?q=461-78-9&cat=
Chemspace
CSSS00015360950
https://chem-space.com/CSSS00015360950
Debye Scientific
DB-013307
http://www.debyesci.com/cas_461-78-9.html
Finetech
FT-0683062
http://www.finetechnology-ind.com/product/All%20product%20List/461-78-9.html
J&W PharmLab
20R0905
https://www.jwpharmlab.com/home/product/20R0905
mcule
MCULE-9625062817
https://mcule.com/MCULE-9625062817/
Oakwood
368038
http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=139694&ExtHyperLink=1
Smolecule
S523550
http://www.smolecule.com/products/s523550
Synblock Inc
AB02276
http://www.synblock.com/product/461-78-9.html
THE BioTek
bt-264209
https://www.thebiotek.com/product/inhibitors/bt-264209
PubMed

PubMed

TitleDatePubMed
Successful drug development despite adverse preclinical findings part 2: examples.
2010-12
Pulmonary hypertension associated with use of phentermine.
2010-11
Insight into human alveolar macrophage and M. tuberculosis interactions via metabolic reconstructions.
2010-10-19
Gene expression in lungs of mice lacking the 5-hydroxytryptamine transporter gene.
2009-05-10
The antidotal effects of high-dosage gamma-aminobutyric acid on acute tetramine poisoning as compared with sodium dimercaptopropane sulfonate.
2007-08
The use of parotid gland activity analysis in patients with gastro-esophageal reflux disease (GERD) and bulimia nervosa.
2006
Screening for amphetamine and amphetamine-type drugs in doping analysis by liquid chromatography/mass spectrometry.
2006
Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis.
2002
The effect of fenfluramine on the pulmonary disposition of 5-hydroxytryptamine in the isolated perfused rat lung: a comparison with chlorphentermine.
2000-01
The early changes in experimental myopathy induced by chloroquine and chlorphentermine.
1980-01
Experimental myopathy induced by amphiphilic cationic compounds including several psychotropic drugs.
1979
Chlorphentermine, a new anorectic agent.
1962-09
Patents

Patents

EP2305227B1
2

Sample Use Guides

In Vivo Use Guide
Adults: 65 mg (one tablet) taken with or shortly after the first meal of the day.
Route of Administration: Oral
In Vitro Use Guide
In contrast, lymphocytes pre-incubated with 10(-5)M chlorphentermine (CP) for 60 min, then stimulated with Con A for 2 hours in the presence of 10(-5)M CP, exhibit a significantly depressed inositol phosphate formation. In addition, CP also inhibited the activity of phospholipase C (IC50 = 0.58 mM), the enzyme responsible for the formation of inositol phosphates during lymphocyte activation. Further, lymphocytes activated in a manner that bypasses the phosphatidylinositol pathway are not inhibited by 10(-7)M or 10(-9)M CP as are cells activated with Con A.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:35:38 GMT 2025
Edited
by admin
on Mon Mar 31 17:35:38 GMT 2025
Record UNII
RL11HOJ7DM
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CHLORPHENTERMINE HYDROCHLORIDE
MART.   MI   ORANGE BOOK   USAN   WHO-DD  
USAN  
Official Name English
PRE-SATE
Preferred Name English
CHLORPHENTERMINE HYDROCHLORIDE [USAN]
Common Name English
CHLORPHENTERMINE HCL
Common Name English
Chlorphentermine hydrochloride [WHO-DD]
Common Name English
P-CHLORO-.ALPHA.,.ALPHA.-DIMETHYLPHENETHYLAMINE HYDROCHLORIDE
Common Name English
NSC-76098
Code English
CHLORPHENTERMINE HYDROCHLORIDE [MI]
Common Name English
S-62
Code English
W-2426
Code English
BENZENEETHANAMINE, 4-CHLORO-.ALPHA.,.ALPHA.-DIMETHYL-, HYDROCHLORIDE
Systematic Name English
CHLORPHENTERMINE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
CHLORPHENTERMINE HYDROCHLORIDE [MART.]
Common Name English
W 2426
Code English
Classification Tree Code System Code
NCI_THESAURUS C47795
Created by admin on Mon Mar 31 17:35:38 GMT 2025 , Edited by admin on Mon Mar 31 17:35:38 GMT 2025
DEA NO. 1645
Created by admin on Mon Mar 31 17:35:38 GMT 2025 , Edited by admin on Mon Mar 31 17:35:38 GMT 2025
Code System Code Type Description
FDA UNII
RL11HOJ7DM
Created by admin on Mon Mar 31 17:35:38 GMT 2025 , Edited by admin on Mon Mar 31 17:35:38 GMT 2025
PRIMARY
NSC
76098
Created by admin on Mon Mar 31 17:35:38 GMT 2025 , Edited by admin on Mon Mar 31 17:35:38 GMT 2025
PRIMARY
EPA CompTox
DTXSID1047815
Created by admin on Mon Mar 31 17:35:38 GMT 2025 , Edited by admin on Mon Mar 31 17:35:38 GMT 2025
PRIMARY
NCI_THESAURUS
C65324
Created by admin on Mon Mar 31 17:35:38 GMT 2025 , Edited by admin on Mon Mar 31 17:35:38 GMT 2025
PRIMARY
ECHA (EC/EINECS)
205-782-9
Created by admin on Mon Mar 31 17:35:38 GMT 2025 , Edited by admin on Mon Mar 31 17:35:38 GMT 2025
PRIMARY
MERCK INDEX
m3458
Created by admin on Mon Mar 31 17:35:38 GMT 2025 , Edited by admin on Mon Mar 31 17:35:38 GMT 2025
PRIMARY Merck Index
PUBCHEM
65477
Created by admin on Mon Mar 31 17:35:38 GMT 2025 , Edited by admin on Mon Mar 31 17:35:38 GMT 2025
PRIMARY
ChEMBL
CHEMBL1201269
Created by admin on Mon Mar 31 17:35:38 GMT 2025 , Edited by admin on Mon Mar 31 17:35:38 GMT 2025
PRIMARY
SMS_ID
100000084738
Created by admin on Mon Mar 31 17:35:38 GMT 2025 , Edited by admin on Mon Mar 31 17:35:38 GMT 2025
PRIMARY
DRUG BANK
DBSALT000815
Created by admin on Mon Mar 31 17:35:38 GMT 2025 , Edited by admin on Mon Mar 31 17:35:38 GMT 2025
PRIMARY
EVMPD
SUB01251MIG
Created by admin on Mon Mar 31 17:35:38 GMT 2025 , Edited by admin on Mon Mar 31 17:35:38 GMT 2025
PRIMARY
CAS
151-06-4
Created by admin on Mon Mar 31 17:35:38 GMT 2025 , Edited by admin on Mon Mar 31 17:35:38 GMT 2025
PRIMARY
Related Record Type Details
Structure of CHLORPHENTERMINE
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of CHLORPHENTERMINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966